BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a one year consensus price objective of $8.50 for the company and are forecasting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given BrainStorm Cell Therapeutics an industry rank of 107 out of 265 based on the ratings given to its competitors.

Separately, Maxim Group set a $5.00 target price on BrainStorm Cell Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of BrainStorm Cell Therapeutics (NASDAQ:BCLI) traded down 0.4174% during midday trading on Friday, reaching $2.4099. The company’s stock had a trading volume of 20,115 shares. BrainStorm Cell Therapeutics has a 1-year low of $1.90 and a 1-year high of $3.87. The company’s 50-day moving average price is $2.44 and its 200 day moving average price is $2.43. The firm’s market capitalization is $44.95 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Thursday, August 11th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.13. On average, equities research analysts forecast that BrainStorm Cell Therapeutics will post ($0.34) earnings per share for the current year.

A hedge fund recently raised its stake in BrainStorm Cell Therapeutics stock. Vanguard Group Inc. increased its stake in BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 1.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 491,867 shares of the biotechnology company’s stock after buying an additional 6,200 shares during the period. Vanguard Group Inc. owned 2.64% of BrainStorm Cell Therapeutics worth $1,186,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.74% of the company’s stock.

About BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

5 Day Chart for NASDAQ:BCLI

Get a free copy of the Zacks research report on BrainStorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BrainStorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainStorm Cell Therapeutics Inc. and related companies with's FREE daily email newsletter.